| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
46,205 |
42,254 |
$3.18M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
54,167 |
50,805 |
$1.90M |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
8,715 |
8,257 |
$1.16M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
12,741 |
12,306 |
$698K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
11,005 |
10,524 |
$596K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
8,582 |
8,141 |
$461K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
8,024 |
7,802 |
$454K |
| 87631 |
|
4,751 |
4,487 |
$404K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
7,068 |
6,720 |
$332K |
| 87428 |
|
2,186 |
2,077 |
$150K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
9,861 |
9,314 |
$117K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
989 |
958 |
$115K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,862 |
1,700 |
$109K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
3,939 |
3,724 |
$91K |
| 90670 |
|
7,342 |
7,055 |
$79K |
| 90647 |
|
5,944 |
5,699 |
$70K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
6,573 |
6,189 |
$68K |
| 90723 |
|
5,916 |
5,707 |
$64K |
| 83655 |
|
2,987 |
2,871 |
$49K |
| 99381 |
|
909 |
852 |
$48K |
| 87807 |
|
3,570 |
3,351 |
$43K |
| 90707 |
|
3,757 |
3,564 |
$40K |
| 90716 |
|
3,722 |
3,536 |
$40K |
| 90633 |
|
3,756 |
3,572 |
$40K |
| 90680 |
|
3,534 |
3,404 |
$38K |
| 81001 |
|
6,781 |
6,335 |
$28K |
| 90651 |
|
2,545 |
2,402 |
$27K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
617 |
576 |
$25K |
| 99215 |
Prolong outpt/office vis |
226 |
210 |
$23K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
758 |
743 |
$21K |
| 90734 |
|
1,857 |
1,734 |
$20K |
| 90619 |
|
655 |
632 |
$14K |
| 86308 |
|
2,045 |
1,922 |
$14K |
| 90686 |
|
965 |
921 |
$14K |
| 85018 |
|
4,112 |
3,951 |
$13K |
| 90715 |
|
830 |
788 |
$9K |
| 90696 |
|
745 |
696 |
$8K |
| 90688 |
|
846 |
810 |
$8K |
| 90677 |
|
506 |
497 |
$6K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
134 |
110 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
395 |
351 |
$5K |
| 90700 |
|
424 |
409 |
$4K |
| 96112 |
|
24 |
24 |
$4K |
| 69210 |
|
81 |
71 |
$2K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
278 |
276 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
69 |
64 |
$1K |
| 90674 |
|
68 |
60 |
$934.49 |
| 99383 |
|
14 |
14 |
$733.33 |
| 99384 |
|
14 |
12 |
$671.11 |
| T1502 |
Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit |
365 |
356 |
$532.80 |
| 96127 |
|
103 |
98 |
$401.44 |
| 90656 |
|
17 |
17 |
$262.65 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
15 |
12 |
$177.60 |
| 90658 |
|
17 |
17 |
$162.52 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
26 |
22 |
$0.00 |